SCHEMBL20284866

SCHEMBL20284866

CC(C)CC(NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCN(C)CC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NC(CC(C)C)C(=O)[C@@]1(C)CO1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 18/20 0.85
PSMB2 P49721 4/20 0.85
PSMB8 P28062 3/20 0.85
PSMB10 P40306 3/20 0.85
PSMB9 P28065 3/20 0.85
PSMB1 P20618 2/20 0.85
PSMB11 A5LHX3 1/20 0.85
PSMD11 O00231 1/20 0.85
PSMD12 O00232 1/20 0.85
PSMD14 O00487 1/20 0.85
PSMA7 O14818 1/20 0.85
PSMD3 O43242 1/20 0.85
CTSB P07858 1/20 0.85
CYP3A4 P08684 1/20 0.85
PSMC3 P17980 1/20 0.85
CYP3A5 P20815 1/20 0.85
CYP3A7 P24462 1/20 0.85
PSMA1 P25786 1/20 0.85
PSMA2 P25787 1/20 0.85
PSMA3 P25788 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13019472 1.00 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL21156750 1.00 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL20284802 1.00 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL16104627 1.00 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL2633232 1.00 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL19289616 1.00 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL8267593 1.00 PSMB5 (0.85) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL22852721 0.97 PSMB5 (0.80) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL21192146 0.97 PSMB5 (0.80) PSMB5PSMB2PSMB8PSMB10PSMB9
SCHEMBL20284796 0.96 PSMB5 (0.81) PSMB5PSMB2PSMB8PSMB10PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200325172-A1 Compounds for proteasome enzyme inhibition PROTEOLIX, INC. 2020-10-15 US disclosed
US-20200289606-A1 PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS ONYX THERAPEUTICS INC (US) 2020-09-17 US disclosed
US-20200071356-A1 COMPOUNDS FOR PROTEASOME PROTEOLIX, INC. 2020-03-05 US disclosed
US-20190211058-A1 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION PROTEOLIX, INC. 2019-07-11 US disclosed
US-20180170962-A1 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION ONYX THERAPEUTICS INC (US) 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289606-A1 PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS PIM1, PIM2, PIM3 PSMB5 57/4885PSMB2 12/4885PSMB8 25/4885
US-20180170962-A1 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION PSMB1, PSMB9, PSMB3 PSMB5 14/4885PSMB2 5/4885PSMB8 27/4885
US-20200071356-A1 COMPOUNDS FOR PROTEASOME PSMB1, PSMB9, PSMB2 PSMB5 12/4885PSMB2 3/4885PSMB8 20/4885
US-20200325172-A1 Compounds for proteasome enzyme inhibition PSMB1, PSMB9, PSMB3 PSMB5 14/4885PSMB2 5/4885PSMB8 27/4885
US-20190211058-A1 COMPOUNDS FOR PROTEASOME ENZYME INHIBITION PSMB1, PSMB9, PSMB3 PSMB5 14/4885PSMB2 5/4885PSMB8 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.